Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed
therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in
patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed
will be obtained.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
BB 1101 Dexamethasone Dexamethasone 21-phosphate Dexamethasone acetate Folic Acid Hydroxocobalamin Nintedanib Pemetrexed Vitamin B 12 Vitamin B Complex